Importantly, our results show that the CHK1 inhibitor, rabusertib was able to overcome resistance to cisplatin in a resistant model of breast cancer, suggesting its potential use in combination in patients presenting with resistance to platinum agents [27]. The gene discussed is CHEK1; the disease is breast carcinoma.